Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
about
Development of selective non-peptide angiotensin II type 2 receptor agonists.Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?Postnatal acute renal failure after fetal exposure to angiotensin receptor blockersAngiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progressionNovel insights in the treatment of diabetic nephropathy.Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade.Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects.Discordant responses to two classes of drugs acting on the renin-angiotensin system.Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.Gene therapy for hypertension and restenosis.Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers.Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.Evaluation of enalapril+losartan treatment with cardiopulmonary exercise test in patients with left ventricular dysfunction.Validated LC-MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies.Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine
P2860
Q33514251-B1B40213-4876-4F2A-A540-A28407A98285Q34610040-C2C07A56-37EC-4587-99E3-213DA8FFB774Q35013827-4E5D4BD9-B62D-42A6-9808-B19E88F7CF01Q35823635-01503FF1-6618-429A-9BB8-771FE4CAAFA4Q35876800-7F5D2846-7180-40B7-ADF3-8EBA5044658CQ37070946-4907CF5C-3481-4909-AC7A-FA1F5005624BQ37343667-3B2B8BB6-F354-4489-806E-7F5A1C94C78DQ42645323-3307B38F-712D-46BD-897A-7A11C277A23BQ43613485-6FD43742-76E5-4ED2-A83D-FA416D435845Q43907234-373DF272-2C94-48D2-80A7-D42F7CF42B10Q44452204-839096E1-0A4A-4D9F-A5B2-BC22A9B28AA2Q45883966-FCF735AB-EA58-4B57-A548-5BD784CFD88BQ46079624-C28A1F05-0667-40D4-89C9-491C5EBFCED7Q46479802-3959088E-61CA-4518-8FC4-6D2E38D83B4CQ46976515-308652E8-234F-4ECF-989F-6455DF4538D6Q50591321-B1683DB3-CBBD-4855-BDD5-7F368C0CE0C5Q57995102-408C1D4A-AC57-4D5A-9789-582E14841718
P2860
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@ast
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@en
type
label
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@ast
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@en
prefLabel
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@ast
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@en
P1476
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.
@en
P2093
Birkenhäger WH
P304
P356
10.1097/00004872-199917070-00002
P577
1999-07-01T00:00:00Z